Shu Lian, Cui Xinhan, Wang Yan, Sun Xinghuai
Department of Ophthalmology & Visual Science, Eye & ENT Hospital, Shanghai Medical College, Fudan University, No.83 Fenyang Road, Shanghai, 200031, China.
State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai, China.
BMC Ophthalmol. 2025 Apr 14;25(1):206. doi: 10.1186/s12886-025-04043-6.
Cyclin-dependent kinase (CDK) 4/6 inhibitors are novel anticancer drugs that can arrest the cell cycle and halt the progression of cancers. This study presents a rare case of vortex keratopathy associated with the use of a cyclin-dependent kinase (CDK) 4/6 inhibitor for breast cancer treatment.
A 60-year-old female patient with a one-year history of eye irritation presented at our hospital. She had been diagnosed with metastatic breast cancer two years prior and received treatment with tiremciclib (a novel CDK4/6 inhibitor) in combination with fulvestrant at the same time. After slit-lamp examination, anterior segment optical coherence tomography (AS-OCT), and corneal confocal microscopy, the patient was diagnosed with vortex keratopathy. The ocular symptoms of the patient improved slightly after the use of artificial lubricating eye drops.
This case demonstrates the ocular characteristics and novel findings of corneal confocal microscopy of CDK4/6 inhibitor-related vortex keratopathy. Our findings increase the understanding of the pathophysiological mechanisms of drug-induced vortex keratopathy and increase our awareness of ocular manifestations in patients receiving novel anticancer drugs.
细胞周期蛋白依赖性激酶（CDK）4/6抑制剂是一类新型抗癌药物，可使细胞周期停滞，阻止癌症进展。本研究报告了1例与使用细胞周期蛋白依赖性激酶（CDK）4/6抑制剂治疗乳腺癌相关的涡状角膜病变罕见病例。
一名有1年眼部刺激史的60岁女性患者前来我院就诊。她两年前被诊断为转移性乳腺癌，同时接受了哌柏西利（一种新型CDK4/6抑制剂）联合氟维司群治疗。经过裂隙灯检查、眼前节光学相干断层扫描（AS-OCT）和角膜共焦显微镜检查，该患者被诊断为涡状角膜病变。使用人工润滑眼药水后，患者的眼部症状略有改善。
本病例展示了CDK4/6抑制剂相关涡状角膜病变的眼部特征及角膜共焦显微镜检查的新发现。我们的研究结果增进了对药物性涡状角膜病变病理生理机制的理解，并提高了我们对接受新型抗癌药物治疗患者眼部表现的认识。
